Evidence map›Paper›PMID 35233581›Full record

ArticlemedRxiv : the preprint server for health sciences2022

Influenza vaccination and single cell multiomics reveal sex dimorphic immune imprints of prior mild COVID-19.

Rachel Sparks, William W Lau, Can Liu, Kyu Lee Han, Kiera L Vrindten, Guangping Sun, Milann Cox, Sarah F Andrews, Neha Bansal, Laura E Failla and 18 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors.

Rachel SparksMultiscale Systems Biology Section, Laboratory of Immune System Biology, NIAID, NIH, Bethesda, MD, USA.
William W LauMultiscale Systems Biology Section, Laboratory of Immune System Biology, NIAID, NIH, Bethesda, MD, USA.
Can LiuMultiscale Systems Biology Section, Laboratory of Immune System Biology, NIAID, NIH, Bethesda, MD, USA.
Kyu Lee HanNIH Center for Human Immunology, NIAID, NIH, Bethesda, MD, USA.
Kiera L VrindtenMultiscale Systems Biology Section, Laboratory of Immune System Biology, NIAID, NIH, Bethesda, MD, USA.
Guangping SunMultiscale Systems Biology Section, Laboratory of Immune System Biology, NIAID, NIH, Bethesda, MD, USA.
Milann CoxMultiscale Systems Biology Section, Laboratory of Immune System Biology, NIAID, NIH, Bethesda, MD, USA.
Sarah F AndrewsVaccine Research Center, NIAID, NIH, Bethesda, MD, USA.
Neha BansalMultiscale Systems Biology Section, Laboratory of Immune System Biology, NIAID, NIH, Bethesda, MD, USA.
Laura E FaillaMultiscale Systems Biology Section, Laboratory of Immune System Biology, NIAID, NIH, Bethesda, MD, USA.
Jody ManischewitzDivision of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, USA.
Gabrielle GrubbsDivision of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, USA.
Lisa R KingDivision of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, USA.
Galina KorolevaNIH Center for Human Immunology, NIAID, NIH, Bethesda, MD, USA.
Stephanie LeimenstollLaboratory of Clinical Immunology and Microbiology, NIAID, NIH, Bethesda, MD, USA.
LaQuita SnowLaboratory of Clinical Immunology and Microbiology, NIAID, NIH, Bethesda, MD, USA.
OP11 Clinical Staff
Jinguo ChenNIH Center for Human Immunology, NIAID, NIH, Bethesda, MD, USA.
Juanjie TangDivision of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, USA.
Amrita MukherjeeNIH Center for Human Immunology, NIAID, NIH, Bethesda, MD, USA.
Brian A SellersNIH Center for Human Immunology, NIAID, NIH, Bethesda, MD, USA.
Richard AppsNIH Center for Human Immunology, NIAID, NIH, Bethesda, MD, USA.
Adrian B McDermottVaccine Research Center, NIAID, NIH, Bethesda, MD, USA.
Andrew J MartinsMultiscale Systems Biology Section, Laboratory of Immune System Biology, NIAID, NIH, Bethesda, MD, USA.
Evan M BlochDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Hana GoldingDivision of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, USA.
Surender KhuranaDivision of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, USA.
John S TsangMultiscale Systems Biology Section, Laboratory of Immune System Biology, NIAID, NIH, Bethesda, MD, USA.

Funding

Vaccine Immunology ProgramZIAAI005143 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI KOUP, RICHARD A · 2019 to 2025
$51.8M
Integrative analysis and modeling of human immune responses and pathologiesZIAAI001152 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI TSANG, JOHN · 2011 to 2022
$14.1M
Systems Immunology of COVID-19ZIAAI001266 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI TSANG, JOHN · 2020 to 2022
$1.2M
Systems immunology of influenza vaccination responses in healthy COVID-19 recovered individual versus those with no history of COVID-19ZIAAI001359 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI SPARKS, RACHEL · 2022 to 2023
$762k
6 · The paper itself

Abstract

Viral infections can have profound and durable functional impacts on the immune system. There is an urgent need to characterize the long-term immune effects of SARS-CoV-2 infection given the persistence of symptoms in some individuals and the continued threat of novel variants. Here we use systems immunology, including longitudinal multimodal single cell analysis (surface proteins, transcriptome, and V(D)J sequences) from 33 previously healthy individuals after recovery from mild, non-hospitalized COVID-19 and 40 age- and sex-matched healthy controls with no history of COVID-19 to comparatively assess the post-infection immune status (mean: 151 days after diagnosis) and subsequent innate and adaptive responses to seasonal influenza vaccination. Identification of both sex-specific and -independent temporally stable changes, including signatures of T-cell activation and repression of innate defense/immune receptor genes (e.g., Toll-like receptors) in monocytes, suggest that mild COVID-19 can establish new post-recovery immunological set-points. COVID-19-recovered males had higher innate, influenza-specific plasmablast, and antibody responses after vaccination compared to healthy males and COVID-19-recovered females, partly attributable to elevated pre-vaccination frequencies of a GPR56 expressing CD8+ T-cell subset in male recoverees that are "poised" to produce higher levels of IFNγ upon inflammatory stimulation. Intriguingly, by day 1 post-vaccination in COVID-19-recovered subjects, the expression of the repressed genes in monocytes increased and moved towards the pre-vaccination baseline of healthy controls, suggesting that the acute inflammation induced by vaccination could partly reset the immune states established by mild COVID-19. Our study reveals sex-dimorphic immune imprints and

Identifiers

PMID35233581
PMCPMC8887138

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.